Morgantown, WV

United BioSource LLC

Tremor

Polyneuropathies

Pregnancy Complications

Crohn Disease

Neuroendocrine Carcinoma

Diabetes Mellitus

Thyroid Diseases

Multiple Sclerosis

Essential Tremor

Myasthenia Gravis

Epidiolex

Ulixacaltamide

Epidyolex

Biogen

Jazz Pharmaceuticals

Novo Nordisk

Praxis Precision Medicines

argenx

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The goal of this clinical study is to compare ulixacaltamide and placebo treatment in essential tremor. The main question it aims to answer is:

• Is ulixacaltamide a safe and efficacious treatment for patients with essential tremor?

Participants will be asked to participate in one of two clinical studies where they will be treated with either ulixacaltamide or placebo for a period of up to 12 weeks. After the controlled study completion, they will be eligible to participate in a long-term, open-label safety study and be treated with ulixacaltamide.

Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)

United BioSource LLC | Morgantown, WV

Site insights

Work at this site?

Active trials

Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)

Trial sponsors